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Abstract
Ebola virus disease (EVD) has existed as a major health concern with devastating and, many times, fatal symptoms. The
recent outbreaks of EVD in West Africa and the Democratic
Republic of the Congo (DRC) have incited international concern. In this article, the implications of EVD will be discussed
including the etiology, transmission, signs and symptoms,
diagnosis and treatment of the disease. In addition to this
discussion, the manner in which major health care organjzations, including the World Health Organization (WHO), are
dealing with treating infected patients and containing spread
of the disease will be covered.
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Introduction
International attention has recently focused on the fatalities
caused by the Ebola virus disease (EVD). Previously known
as Ebola hemorrhagic fever when first discovered in 1976,
EVD has become an epidemic. Two cases occurred simultaneously in Sudan and DRC. The current outbreak has spread
outside of Africa and 13,675 laboratory-confirmed cases
were reported to WHO and the Centers for Disease Control
and Prevention (CDC) between December 2013 and January
2015.1·6 On Oct. 4, 2014, a case of Ebola virus disease was
confirmed in the United States by the CDC and there have, in
total, been four cases of EVD treated in the United States to
date.2 With the recent outbreak, fear and questions surrounding EVD have risen; health care professionals have a
duty to respond to patient concerns about EVD. This article
will discuss the etiology, transmission, symptoms and treatment of EVD.
Disease Etiology
Ebola virus disease is native to regions of Africa. Its natural
reservoir is unknown but is believed to be fruit bats.1,4 There
are five species of viruses of the ebolavirus genus, four of
which are known to cause disease in humans. Each is named
for the geographical location from which it originated.
Ebola virus, or Zaire ebolavirus, first identified in DRC, is the
species associated with the highest mortality rate, and the
species of the current 2014 outbreak.3.s
The current outbreak has spread over West Africa in the
countries of Guinea, Liberia and Sierra Leone with a total of
22,057 cases reported, and 13,675 of those cases being laboratory confirmed Ebola virus.6 Because this outbreak has
affected areas of large population, the increased rate of
transmission makes this the largest outbreak to date. There
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are four reported cases confirmed in the United States (two
travel-associated and two locally acquired) and one travelassociated case in Spain. There were also 66 documented
cases of Ebola virus in DRC, but they are not associated with
the current outbreak in West Africa. However, with the outbreak in DRC having no new cases since November, the outbreak was declared over on Nov. 21, 2014.7 Patient zero of
the West Africa outbreak was a pregnant woman from lkanamongo Village who handled bush meat and became ill with
symptoms consistent with Ebola virus. She died on Aug. 11,
2014, and several health care workers were exposed to the
virus. No one associated with this outbreak reported traveling to the areas of West Africa where the largest outbreak
originated.7 Those who have come in contact with wildlife
infected with Ebola virus are at high risk for infection, as the
virus can be transmitted through improperly cooked meat or
contact with the animal's bodily fluid. Health care workers
taking care of infected individuals and people who have had
close contact with the patients' bodily fluids are at greatest
risk for contracting the infection.
The ebolaviruses are negative-sense ribonucleic acid (RNA)
viruses.s The exact mechanism for how the virus damages
host cells and causes infection has not been clearly studied
due to limited research resources in the areas of Africa
where the virus is found. However, certain evidence has suggested that the specific glycoproteins on the viral surface
envelope attribute to certain progressive properties of the
disease. One glycoprotein (GP) contributes to the hemorrhagic symptoms by allowing the virus to insert its contents
into monocytes and endothelial cells, causing a release of
cytokines leading to inflammation and damage to host blood
vessels, respectively. Another GP, sGP, binds to and inhibits neutrophils. This suppression of the host's immune response allows
the virus to infect the host unopposed. Furthermore, infected
neutrophils transport the virus to the lymph nodes, liver and
spleen, which increases the perpetuation of the infection
Transmission
With limited treatment options for EVD, it is important to
reduce the spread and transmission of the virus among hosts
because the virus is thought to originate in fruit bats. Individuals are not only warned to avoid contact with these animals,
but also other wildlife including monkeys, chimpanzees, gorillas, forest antelope and porcupines.1 In addition to avoiding the blood, organs, secretions or other fluids from these
animals, individuals should refrain from consuming raw
meat from any potentially infected species.a Live-animal
market places are often the culprit of animal to human transmission for a multitude of diseases due to the vast exposure
and the mixing of different species. This, combined with
poor hand hygiene, results in a greater risk of transmission

THE PHARMACY AND WELLNESS REVIEW

23

Infectious Disease

Outbreak of Ebola Virus Disease

of Ebola from animals to humans.9 It is important to practice
meticulous hand hygiene to not only prevent the transmission of the virus from wildlife but also from other humans.a
Ebola virus is spread from human to human by direct contact. Individuals may acquire the virus by directly touching
any body fluids including blood, semen, feces, saliva, urine
and vomit of an infected individual, which then enters
through broken skin or a mucous membrane. The virus can
also be spread indirectly across surfaces or materials that are
contaminated with any such infected body fluids.1 Perhaps
the best way to prevent the transmission from person to person is to avoid any and all blood or body fluids as well as
careful hand washing with soap and water or an alcoholbased cleanser.swearing gloves while handling animals or
contaminated individuals is also recommended. Communities in affected areas are advised to avoid funeral or burial
rituals that include direct contact of those who have died of
Ebola.1.s As long as the blood and body fluids of the deceased
contain the virus, the individual is considered infectious;
thus, facilitating a role in the transmission of the virus.1 In
those areas of outbreak, the WHO suggests quarantining the
sick individuals from the healthy individuals and closely
monitoring one's health for 21 days if possible exposure has
occurred. This 21-day quarantine coincides with the incubation period, or the period of time from infection of the virus
until symptoms appear. If no symptoms of Ebola occur within
the 21 days, the individual may return to a normal lifestyle.
Health care workers are at significant risk for contracting
Ebola virus. Their close contact and direct care with patients
infected with the virus increases the potential for transmission of the disease. Due to the nonspecific signs and symptoms of the virus in the beginning stages, the importance of
using personal protective equipment in all patient cases regardless of diagnosis is stressed to all health care personne1.10 Protective devices such as two pairs of gloves, a gown,
nonpermeable shoes and a face mask should be put on before
entering patient areas and worn during direct care to prevent transmission of the virus Health care facilities are encouraged to place an infected patient in isolation and limit
access to those directly caring for that patient. Supplies such
as medications, syringes, stethoscopes, thermometers and
other frequently used equipment should be kept directly in
the room to avoid spreading the virus from one area to another. Visitors should be limited or prohibited during the
time of treatment for the infected individual and health care
workers should keep a distance of at least one meter from
the patient if not providing direct care. The disposal and containment of any needles, linens or wastes should be handled
separately from other medical discarded products, and containers should be clearly labeled and disinfected before leaving the isolation area. The WHO stresses the importance of
engagement and awareness of the transmission of Ebola for
not only health care workers but also for the community as a
whole.1 Case management and containment, as well as thorough adherence to personal protection, may help limit the
transmission of Ebola virus for all individuals. Risk reduction
should be a central focus regarding the transmission of tthis
disease.
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Signs and Symptoms
The incubation period for the virus is extended and varied.
The time from infection to symptom presentation is two to
21 days, the average being eight to 10 days.4 ·9·11 Once onset
of symptoms has occurred, the virus is contagious and can be
spread to other people in close contact with the patient.4
• Early symptoms after the incubation period can include:4,9,11.12
sudden onset of fever at least 101°F (38.3°C)
0
malaise
headache
sore throat
muscle pain/weakness
0
lower back pain
nausea/vomiting/ diarrhea
• Late symptoms are far more severe and fatal including:
unexplained hemorrhaging from eyes, ears,
nose, mouth or rectum
impaired kidney and liver function
eye swelling
genital swelling
extensive blood-containing body rash
Diagnosis
Ebola virus disease is diagnosed using a variety of tests, as
early symptomatology, alone, does not distinguish it apart
from other diseases such as influenza, typhoid fever, meningitis and malaria. For these reasons, early diagnosis can be
difficult; if a person is experiencing early symptoms and has
been exposed to the fluids of a person or animal infected
with Ebola, or has recently traveled to areas that are experiencing an outbreak, that person should seek medical care
immediately. Isolation is imperative and samples from the
patient should be tested for confirmation of infection.11 The
tests include:4,9,11
• Nonspecific:
Complete blood count
Liver function tests
Coagulation studies
• Specific:
Antigen-capture enzyme-linked immunosorbent
assay (ELISA)
Antibody-capture ELISA
Reverse transcriptase polymerase chain reaction (RT-PCR) assay
Virus isolation by cell culture
Serum neutralization test
Electron microscopy
Treatment
There are currently no approved treatments or vaccines for
EVD in humans.13 Isolation of EVD-infected individuals is
perhaps the most important component of current therapy.
With no approved treatments and high death rates of those
infected, prevention of the spread of the virus is key. Current
therapy consists only of supportive care.a The rapid spread
of EVD in the body along with its ability to interfere with
blood clotting and electrolyte balance commonly leads to
dehydration in infected individuals. Utilization of oral or intravenous electrolyte-containing fluids for rehydration is
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important in maintaining appropriate intravascular volume
and blood pressure. Electrolyte levels, blood pressure, organ
function and patient comfort must be monitored closely.
Changes in fluid administration should be made accordingly
in order to avoid further complications such as multi-organ
failure, shock and death. If multi-organ failure occurs, organ
transplant will provide the most successful survival rates.
Organ support through dialysis and maintaining adequate
blood flow is crucial to keep EVD-infected patients alive and
strong enough to fight infection. In cases of disseminated
intravascular coagulation, heparin and clotting factors
should be given if needed for excess clotting or mass bleeding, respectively. Maintaining oxygen status through ventilation as well as preventing further infection through proper
isolation and aseptic technique are critical components in the
treatment of EVD-infected patients. The specific supportive
care varies from patient to patient based on their presenting
symptoms and individualized needs. The key is ensuring the
patient is comfortable while restoring optimal organ function
to adequately prevent mortality.
While there are no treatments or vaccines currently available
for clinical use, there are several under investigation. Compassionate use of these investigational options is controversial because the safety and efficacy has not been adequately
studied.14 However, the WHO states that in certain circumstances of the current outbreak and with specified conditions
met, it is ethical to use unproven treatment and/or vaccines
in order to provide optimal patient care. These specified
conditions include patient groups that will likely have greater benefit than risk while using the agents and those who are
"most likely to generate scientific insights that will inform its
evidence-based use in the next epidemic."14 In these cases,
investigational options are being used under emergency use
protocol. It is important that clinicians know there is a moral
obligation to collect and share all data associated with these
potential treatments.15 Recently, the need for urgent development of both preventative and post-exposure treatment has
risen. There are several mechanistic treatment options being
studied to prevent the spread of EVD, further outbreaks and
acts of bioterrorism.13.16 Potential options include recombinant anti-Ebola monoclonal antibody-based therapy, RNA
interference therapy, preventative adenovirus-based vaccines and, most recently, an antiviral oral nucleotide.s.n
Mapp Biopharmaceutical has developed ZMapp, a combination of three anti-Ebola monoclonal antibodies produced
from Nicotinina plants.14The antibodies bind to the proteins
of Ebola virus and prevent it from spreading in those already
infected. The product first came onto the investigational
therapy map in January 2014 and quantity is currently very
limited due to minimal manufacturing. ZMapp has not been
tested for safety or effectiveness in humans and no randomized controlled trials have been conducted at this point. However, it has been tested in animals and used compassionately
in the treatment of EVD-infected American health care workers who returned to the United States from West Africa after
the recent outbreak. While some individuals given ZMapp
have recovered from the virus, it is unclear whether or not
ZMapp played a significant role. Because it has not yet been
Fall 2014 Volume 6, Issue 1
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studied for safety in humans, the risks and side effect profile
are unknown. A movement for accelerated studying of
ZMapp has been put in place by the company and the U.S.
government with hopes of approval for humans by 2015.8,13
The minimal availability of the product may lengthen the
time to approval as it may take months to produce sufficient
quantity to be used in research.14
A small RNA-interfering molecule developed by Tekmira
Pharmaceuticals, TKM-Ebola, is being studied as another potential treatment option for those exposed to Ebola virus.11
TKM-Ebola is formulated as a stable nucleic acid-lipid particle and works as an inhibitor of an enzyme that catalyzes the
viral RNA replication of Ebola. It binds specifically to L polymerase, VP24, and VP35 regions within the RNA sequence.
The molecule has performed well in animal studies, but has
not yet been approved for safety or efficacy in humans. The
U.S. Food and Drug Administration (FDA) recently eased
safety restrictions and lifted a hold on the experimental molecule giving it opportunity for advancement in its path to
approva1.10 However, human studies have raised safety concerns with the incidence of chills, low blood pressure, nausea
and shortness of breath in healthy humans taking TKMEbola. This could slow the speed of approval of the drug, but
studies are ongoing as Tekmira Pharmaceuticals works to
resolve these issues. Animal studies have shown that it takes
multiple doses of TKM-Ebola to reach efficacy, which is another concern and potential limitation in its use as EVD therapy.
An emergency investigational new drug application (EIND)
by Chimerix, Inc. for brincidofovir has recently been authorized by the FDA.19 Brincidofovir is an oral nucleotide analog
lipid-conjugate. Clinical trials of brincidofovir have progressed to phase III for the use in cytomegalovirus and adenovirus over the past several years. These trials provide data
on the safety and dosing of brincidofovir that can be translated to a potential use in EVD. To date, no evidence of kidney or
bone marrow toxicity has been found in patients treated with
this agent. This lack of toxicity has stimulated further studies
of brincidofovir as a promising treatment option. Chimerix is
working closely with the FDA to progress in the clinical trials
of this agent, as no clinical data has been established yet
Many mechanisms and molecules have been tested for vaccination purposes. Use of a recombinant vesicular stomatitis
virus (VSV) in which the VSV glycoprotein is replaced with a
glycoprotein of Ebola virus has shown protection in studies
of administration in animals.16 It is known as rVSV-EBOV.
Enzyme-linked immunosorbent assays (ELISA) following
administration of rVSV-EBOV have displayed IgG and lgM
antibodies against Ebola virus.U The adenovirus-based vaccine has shown favorable effects when administered in the
live-attenuated form, but shows no protection when administered as an inactivated molecule. This suggests the potency
of the vaccine is largely based on the replication of the virus.
The U.S. government has planned "fast-track development"
for approval of three additional adenovirus vaccine candidates by the National Institutes of Health (NIH) and Thomas
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Jefferson University, Crucell and Profectus Biosciences.1 3
GlaxoSmithKline has collaborated with the National Institute
of Allergy and Infectious Diseases (NIAID) to derive a replication-defective chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd2-ZEBOV) that has rapidly advanced into
clinical phase I evaluation, known as the VRC 207 studly.20
The adenovirus serves to carry genetic material derived from
the Zaire Ebola species and the Sudan Ebola species. The vaccine delivers one part of the Ebola genetic material to human
cells, but rather than replicating it allows the cells receiving
the vaccine to express a single Ebola protein, which prompts
an immune response. In the VRC 207 study, a monovalent
vaccine containing genetic material derived from only the
Zaire Ebola species, as well as a divalent vaccine containing
genetic material derived from both the Zaire Ebola species
and the Sudan Ebola species, began to be tested. The strudy
includes 10 healthy adults receiving the monovalent vaccine
and 10 healthy adults receiving the divalent vaccine. PrelDminary safety and efficacy data will provide information on the
potential benefits and use of this vaccination.
Response from World Health Organization
The passing of Thomas Duncan, the first patient to be treated
for Ebola in the United States after having been exposed to
the general population, has prompted major discussion on
how the United States might deal with containing the disease.
Popular media extensively covered this particular case, raising public concern for the possibility for an outbreak in
America. As of Aug. 28, 2014, the WHO published its threepoint plan with the goal of containing and eliminating Ebola
within the next six to nine months, beginning with the countries that are most severely affected.21 First, the WHO pfans
to fully respond to all areas where "widespread and intense
transmission" are present. The second point is the development and application of full response for those countries that
may have Ebola exposure via localized transmission. Finally,
the WHO hopes to prepare all countries, especially those tthat
border lands with the highest rates of transmission and
those that are major travel hubs, to self-sufficiently deal with
the possibility of exposure.
The CDC has recently released a number of online resources
consistent with the WHO protocols on disease prevention
and readiness, including preparedness checklists to ensure
that the United States is ready for a potential outbreak.22
There are checklists created for emergency medical providers, health care facilities, hospitals, health care coalitions and
for the general public. A typical checklist is charged with
three primary categories, which are "Prepare to Detect,"
"Prepare to Protect," and "Prepare to Respond." Within these
three primary aims are specific metrics to ensure readiness
for the disease. Following the checklist are quick resources
for the personnel who would likely be reading the particular
checklist. In conjunction with these primary readiness materials, the CDC website also currently contains a regularly updated newsfeed of WHO news and information.
Conclusion
The current outbreak of Ebola is a serious, growing epidemic
accompanied with a great amount of worldwide fear. ft is
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important for health care professionals to stay informed and
updated as the disease and resulting panic spread. Their potential close contact with infected patients further adds to
the need to be ready to respond in accordance with WHO
protocol. Early symptoms of the virus can be difficult to differentiate from other common diseases, so it is crucial that
anyone who has come in contact with an infected individual
seeks medical help as soon as possible if experiencing such
symptoms.11 There are currently no approved treatments or
vaccines for EVD in humans, but there are prospects currently in drug development trials that may show promise in
treating and preventing EVD.1 3 Supportive care for those
infected is extremely important as it greatly decreases mortality.a The WHO currently has a plan in place to contain the
current outbreak.21 Both the WHO and CDC have step-bystep protocols available on their websites with the intention
of helping health care facilities prepare and be able to respond in the event an infected individual needs to be treated
at their hospitaJ.2i,22
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